MaltSci 麦伴科研

Appearance

Curated Papers > High-impact authoritative literature on "liquid biopsy"

Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? ​

Literature Information ​

DOI10.1016/j.canlet.2019.10.014
PMID31610267
JournalCancer letters
Impact Factor10.1
JCR QuartileQ1
Publication Year2020
Times Cited94
KeywordsCell-free DNA (cfDNA), Circulating tumor DNA (ctDNA), Circulating tumor cells (CTC), Diagnosis, Ovarian cancer
Literature TypeJournal Article, Research Support, Non-U.S. Gov't, Review
ISSN0304-3835
Pages59-71
Issue468()
AuthorsDu-Bois Asante, Leslie Calapre, Melanie Ziman, Tarek M Meniawy, Elin S Gray

TL;DR ​

This review highlights the potential of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) as minimally-invasive biomarkers for diagnosis, prognostication, and monitoring in ovarian cancer, addressing their ability to reflect tumor burden and guide treatment decisions. The findings underscore the need for further research to resolve existing challenges before these liquid biopsies can be routinely integrated into clinical practice for effective ovarian cancer management.

Search for more papers on MaltSci.com ​

Cell-free DNA (cfDNA) · Circulating tumor DNA (ctDNA) · Circulating tumor cells (CTC) · Diagnosis · Ovarian cancer

Abstract ​

Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment decisions at the time when direct tumor biopsy may be impractical due to its invasive nature, inaccessibility and associated complications. Specifically, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have shown promising results as companion diagnostic biomarkers for screening, prognostication and/or patient surveillance in many cancer types. In ovarian cancer (OC), CTC and ctDNA analysis allow comprehensive molecular profiling of the primary, metastatic and recurrent tumors. These biomarkers also correlate with overall tumor burden and thus, they provide minimally-invasive means for patient monitoring during clinical course to ascertain therapy response and timely treatment modification in the context of disease relapse. Here, we review recent reports of the potential clinical value of CTC and ctDNA in OC, expatiating on their use in diagnosis and prognosis. We critically appraise the current evidence, and discuss the issues that still need to be addressed before liquid biopsies can be implemented in routine clinical practice for OC management.

MaltSci.com AI Research Service ​

Intelligent ReadingAnswer any question about the paper and explain complex charts and formulas
Locate StatementsFind traces of a specific claim within the paper
Add to KBasePerform data extraction, report drafting, and advanced knowledge mining

Primary Questions Addressed ​

  1. What specific challenges remain in standardizing liquid biopsy techniques for ovarian cancer?
  2. How do circulating tumor DNA and circulating tumor cells compare in terms of sensitivity and specificity for detecting ovarian cancer?
  3. What are the implications of liquid biopsy findings on treatment decisions and patient outcomes in ovarian cancer?
  4. In what ways can liquid biopsies be integrated into existing clinical workflows for ovarian cancer management?
  5. What advancements in technology are needed to enhance the accuracy and reliability of liquid biopsies in ovarian cancer?

Key Findings ​

Key Insights ​

  1. Research Background and Objective: The study investigates the utility of liquid biopsies, particularly focusing on circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), in the context of ovarian cancer (OC). Traditional tumor biopsies can be invasive, challenging to access, and may have complications, which highlights the need for less invasive alternatives. The objective is to evaluate whether ctDNA and CTCs can serve as reliable biomarkers for screening, prognosis, and monitoring treatment responses in ovarian cancer patients.

  2. Main Methods and Findings: The review synthesizes recent findings regarding the application of ctDNA and CTCs in ovarian cancer. It emphasizes that these biomarkers allow for comprehensive molecular profiling of tumors, capturing information from primary, metastatic, and recurrent cancer stages. The analysis of ctDNA and CTCs has demonstrated a correlation with overall tumor burden, making them valuable tools for monitoring disease progression and therapy efficacy over time. The review also highlights various studies that support the clinical utility of these liquid biopsy approaches, while acknowledging the variability in methodologies and results across different studies.

  3. Core Conclusions: The findings indicate that ctDNA and CTCs hold significant promise as non-invasive biomarkers for the diagnosis and prognosis of ovarian cancer. They can potentially guide clinical decisions by providing insights into tumor dynamics and treatment responses. However, the review underscores that while the clinical value of liquid biopsies is evident, there are still critical challenges to address before they can be fully integrated into routine clinical practice, such as standardization of methodologies and validation across diverse patient populations.

  4. Research Significance and Impact: The significance of this research lies in its potential to transform ovarian cancer management by facilitating personalized treatment approaches through real-time monitoring of tumor characteristics. The ability to utilize liquid biopsies could not only reduce the need for invasive procedures but also enhance patient outcomes by enabling timely treatment modifications. As the field progresses, addressing the outlined challenges could pave the way for liquid biopsies to become a standard practice in oncology, thereby improving the overall care of ovarian cancer patients and potentially influencing outcomes in other cancer types as well.

Literatures Citing This Work ​

  1. Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study. - Stefano Guadagni;Giammaria Fiorentini;Ioannis Papasotiriou;Panagiotis Apostolou;Francesco Masedu;Donatella Sarti;Antonietta Rossella Farina;Andrew Reay Mackay;Marco Clementi - BMC research notes (2020)
  2. A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer. - Stefano Guadagni;Marco Clementi;Francesco Masedu;Giammaria Fiorentini;Donatella Sarti;Marcello Deraco;Shigeki Kusamura;Ioannis Papasotiriou;Panagiotis Apostolou;Karl Reinhard Aigner;Giuseppe Zavattieri;Antonietta Rossella Farina;Giuseppe Vizzielli;Giovanni Scambia;Andrew Reay Mackay - International journal of molecular sciences (2020)
  3. PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies. - Elizabeth K Lee;Ursula A Matulonis - Cancers (2020)
  4. A New Method for CTC Images Recognition Based on Machine Learning. - Binsheng He;Qingqing Lu;Jidong Lang;Hai Yu;Chao Peng;Pingping Bing;Shijun Li;Qiliang Zhou;Yuebin Liang;Geng Tian - Frontiers in bioengineering and biotechnology (2020)
  5. Liquid biopsy as a perioperative biomarker of digestive tract cancers: review of the literature. - Katsutoshi Shoda;Ryo Saito;Suguru Maruyama;Shinji Furuya;Hidenori Akaike;Yoshihiko Kawaguchi;Hidetake Amemiya;Hiromichi Kawaida;Makoto Sudo;Shingo Inoue;Hiroshi Kono;Daisuke Ichikawa - Surgery today (2021)
  6. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. - Karolin Heinze;Matthias Rengsberger;Mieczyslaw Gajda;Lars Jansen;Linea Osmers;Leticia Oliveira-Ferrer;Barbara Schmalfeldt;Matthias Dürst;Norman Häfner;Ingo B Runnebaum - Clinical epigenetics (2021)
  7. GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions - Riccardo Di Fiore;Sherif Suleiman;Bridget Ellul;Sharon A O'Toole;Charles Savona-Ventura;Ana Felix;Valerio Napolioni;Neil T Conlon;Ilker Kahramanoglu;Miriam J Azzopardi;Miriam Dalmas;Neville Calleja;Mark R Brincat;Yves Muscat-Baron;Maja Sabol;Vera Dimitrievska;Angel Yordanov;Mariela Vasileva-Slaveva;Kristelle von Brockdorff;Rachel A Micallef;Paul Kubelac;Patriciu Achimaș-Cadariu;Catalin Vlad;Olga Tzortzatou;Robert Poka;Antonio Giordano;Alex Felice;Nicholas Reed;C Simon Herrington;David Faraggi;Jean Calleja-Agius - Cancers (2021)
  8. The usefulness of microRNA in urine and saliva as a biomarker of gastroenterological cancer. - Isamu Hoshino - International journal of clinical oncology (2021)
  9. imPlatelet classifier: image-converted RNA biomarker profiles enable blood-based cancer diagnostics. - Krzysztof Pastuszak;Anna Supernat;Myron G Best;Sjors G J G In 't Veld;Sylwia Łapińska-Szumczyk;Anna Łojkowska;Robert Różański;Anna J Żaczek;Jacek Jassem;Thomas Würdinger;Tomasz Stokowy - Molecular oncology (2021)
  10. Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers. - Shuvolina Mukherjee;Karin Sundfeldt;Carl A K Borrebaeck;Magnus E Jakobsson - Proteomes (2021)

... (84 more literatures)

© 2025 MaltSci - We reshape scientific research with AI technology